돌파정신병과 항정신병약물 장기지속형 주사제

키워드

참고문헌 (99)

1. Leucht S, "Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : a systematic review and meta-analysis", Lancet, 379, pp.2063~2071 (2012)
2. Carbon M, "Clinical predictors of therapeutic response to antipsychotics in schizophrenia", Dialogues Clin Neurosci, 16, pp.505~524 (2014)
3. Rubio JM, "Psychosis breakthrough on antipsychotic maintenance : results from a nationwide study", Psychol Med, 50, pp.1356~1367 (2020)
4. Emsley R, "The nature of relapse in schizophrenia", BMC Psychiatry, 13, pp.50~ (2013)
5. Fellner C, "New Schizophrenia Treatments Address Unmet Clinical Needs", P T, 42, pp.130~134 (2017)
6. Robinson D, "Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder", Arch Gen Psychiatry, 56, pp.241~247 (1999)
7. Valenstein M, "Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission", Med Care, 40, pp.630~639 (2002)
8. Morken G, "Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia", BMC Psychiatry, 8, pp.32~ (2008)
9. Alphs L, "Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy", Int Clin Psychopharmacol, 31, pp.202~209 (2016)
10. Kishimoto T, "Longacting injectable versus oral antipsychotics in schizophrenia : a systematic review and meta-analysis of mirror-image studies", J Clin Psychiatry, 74, pp.957~965 (2013)
11. Kane JM, "Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry", J Clin Epidemiol, 66, pp.S37~S41 (2013)
12. Adams CE, "Systematic metareview of depot antipsychotic drugs for people with schizophrenia", Br J Psychiatry, 179, pp.290~299 (2001)
13. Haddad PM, "First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia : systematic review of randomised controlled trials and observational studies", Br J Psychiatry Suppl, 52, pp.S20~S28 (2009)
14. Waddell L, "Attitudes of patients and mental health staff to antipsychotic long-acting injections : systematic review", Br J Psychiatry Suppl, 52, pp.S43~S50 (2009)
15. Correll CU, "The Use of Long-Acting Injectable Antipsychotics in Schizophrenia : Evaluating the Evidence", J Clin Psychiatry, 77, pp.1~24 (2016)
16. Doolabh U, "Examining long-acting injectable antipsychotic(depot)medication in the elderly : a five-year retrospective crosssectional study evaluating depot use in an Australian psychogeriatric service", Australas Psychiatry, 30, pp.31~36 (2022)
17. Paton C, "Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?", Ther Adv Psychopharmacol, 12, pp.20451253211072347~ (2022)
18. Chouinard G, "Neuroleptic-induced supersensitivity psychosis", Am J Psychiatry, 135, pp.1409~1410 (1978)
19. Rubio JM, "Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn?", NPJ Schizophr, 3, pp.36~ (2017)
20. Davis KL, "Is there a limbic system equivalent of tardive dyskinesia?", Biol Psychiatry, 14, pp.699~703 (1979)
21. Nakata Y, "Dopamine supersensitivity psychosis in schizophrenia : Concepts and implications in clinical practice", J Psychopharmacol, 31, pp.1511~1518 (2017)
22. Chouinard G, "Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes", Psychother Psychosom, 77, pp.69~77 (2008)
23. Iyo M, "Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis", J Clin Psychopharmacol, 33, pp.398~404 (2013)
24. Kimura H, "A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis", Schizophr Res, 155, pp.52~58 (2014)
25. Suzuki T, "Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia", Psychiatry Res, 227, pp.278~282 (2015)
26. Takase M, "Dopamine supersensitivity psychosis and dopamine partial agonist : a retrospective survey of failure of switching to aripiprazole in schizophrenia", J Psychopharmacol, 29, pp.383~389 (2015)
27. Fallon P, "A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis", J Psychopharmacol, 25, pp.755~762 (2011)
28. Chouinard G, "Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy", Psychother Psychosom, 86, pp.189~219 (2017)
29. Emsley R, "Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia", Schizophr Res, 225, pp.55~62 (2020)
30. Takekita Y, "New developments in long-acting injectable antipsychotics LAI", Jpn J Clin Psychopharmacol, 24, pp.1079~1087 (2021)
31. Smith RC, "Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine", Life Sci, 19, pp.725~731 (1976)
32. Grace AA, "Dopamine System Dysregulation and the Pathophysiology of Schizophrenia : Insights From the Methylazoxymethanol Acetate Model", Biol Psychiatry, 81, pp.5~8 (2017)
33. Samaha AN, ""Breakthrough"dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time", J Neurosci, 27, pp.2979~2986 (2007)
34. -raclopride PET study in cats, "Neuropsychopharmacology", 2009, 662~671
35. Murugaiah K, "Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum", Nature, 296, pp.570~572 (1982)
36. Seeman P, "Psychosis pathways converge via D2high dopamine receptors", Synapse, 60, pp.319~346 (2006)
37. Murray RM, "Should psychiatrists be more cautious about the longterm prophylactic use of antipsychotics?", Br J Psychiatry, 209, pp.361~365 (2016)
38. Wada M, "Dopaminergic dysfunction and excitatory", inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment, 2022, pp.27, 2950~2967
39. Sachdev PS, "The current status of tardive dyskinesia", Aust N Z J Psychiatry, 34, pp.355~369 (2000)
40. Catts SV, "Reducing long-term antipsychotic use: a therapeutic dead end?", Br J Psychiatry, 210, pp.368~ (2017)
41. Stanley N. Caroff, "Recent Advances in the Pharmacology of Tardive Dyskinesia", Clinical Psychopharmacology and Neuroscience, 18(4), pp.493~506 (2020), 대한정신약물학회[DOI]
42. Seifert R., "Basic Knowledge of Pharmacology" (2019), Springer
43. Kolakowska T, "Schizophrenia with good and poor outcome. III: Neurological ‘soft’ signs, cognitive impairment and their clinical significance", Br J Psychiatry, 146, pp.348~357 (1985)
44. Wistedt B, "Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology", Acta Psychiatr Scand, 67, pp.378~388 (1983)
45. Gardos G, "Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures", Arch Gen Psychiatry, 41, pp.1030~1035 (1984)
46. Palmstierna T, "Tardive psychosis : does it exist?", Psychopharmacology(Berl), 94, pp.144~145 (1988)
47. Dold M, "Dose escalation of antipsychotic drugs in schizophrenia : a meta-analysis of randomized controlled trials", Schizophr Res, 166, pp.187~193 (2015)
48. Tiihonen J, "20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia", Am J Psychiatry, 175, pp.765~773 (2018)
49. Kahn RS, "On the Continued Benefit of Antipsychotics After the First Episode of Schizophrenia", Am J Psychiatry, 175, pp.712~713 (2018)
50. Mace S, "Antipsychotic use and unexpected death : a hospital-based casecontrol study", Acta Psychiatr Scand, 132, pp.479~488 (2015)
51. Vita A, "The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia : Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies", Biol Psychiatry, 78, pp.403~412 (2015)
52. Catts SV, "The treatment of schizophrenia: Can we raise the standard of care?", Aust N Z J Psychiatry, 50, pp.1128~1138 (2016)
53. Lugg W, "Antipsychotic-induced supersensitivity-A reappraisal", Aust N Z J Psychiatry, 56, pp.437~444 (2022)
54. Fountoulakis KN, "The report of the joint WPA", CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia, 2020, 1~25
55. Hojlund M, "Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia : a systematic review and metaanalysis of randomised controlled trials", Lancet Psychiatry, 8, pp.471~486 (2021)
56. Sudo A, "Breakthrough psychotic symptoms on antipsychotic maintenance medication(BAMM)", Jpn J Clin Psychopharmacol, 25, pp.1011~1018 (2022)
57. Rubio JM, "Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders : an individual participant data meta-analysis", Lancet Psychiatry, 7, pp.749~761 (2020)
58. Citrome L, "A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder", Neuropsychiatr Dis Treat, 2, pp.427~ (2006)
59. Kimura H, "Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity", Behav Brain Res, 403, pp.113126~ (2021)
60. Kanahara N, "Recent Discussions on Dopamine Supersensitivity Psychosis : Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia", Curr Neuropharmacol, 19, pp.2214~2226 (2021)
61. Eum S, "Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection : a case report", BMC Psychiatry, 17, pp.238~ (2017)
62. Schoretsanitis G, "Predictors of Lack of Relapse After Random Discontinuation of Oral and Longacting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia : A Re-analysis of Individual Participant Data", Schizophr Bull, 48, pp.296~306 (2022)
63. Takeuchi H, "Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia", Neuropsychopharmacology, 44, pp.1036~1042 (2019)
64. Kane JM, "Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia", CNS Drugs, 35, pp.1189~1205 (2021)
65. Barnes TR, "Evidence-based guidelines for the pharmacological treatment of schizophrenia : Updated recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 34, pp.3~78 (2020)
66. Correll CU, "Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics", Schizophrenia(Heidelb), 8, pp.5~ (2022)
67. Kishimoto T, "Longacting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies", Lancet Psychiatry, 8, pp.387~404 (2021)
68. Kane JM, "Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia : A Randomized Clinical Trial", JAMA Psychiatry, 77, pp.1217~1224 (2020)
69. Tiihonen J, "Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29823 Patients With Schizophrenia", JAMA Psychiatry, 74, pp.686~693 (2017)
70. Lee NY, "A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea", Int Clin Psychopharmacol, 29, pp.279~287 (2014)
71. Samara MT, "Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis", JAMA Psychiatry, 73, pp.199~210 (2016)
72. 윤제연, "‘2019 한국형 조현병 약물치료 지침서’에 따른 조현병에서 동반증상 및 부작용의 치료", 대한조현병학회지, 22(2), pp.21~33 (2019), 대한조현병학회[DOI]
73. Kogure M, "Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis : A 6-Year Retrospective Comparative Study", J Clin Psychopharmacol, 42, pp.357~364 (2022)
74. Samaha AN, "Less is more : antipsychotic drug effects are greater with transient rather than continuous delivery", Biol Psychiatry, 64, pp.145~152 (2008)
75. Kimura H, "Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up", J Psychopharmacol, 30, pp.795~802 (2016)
76. Amato D, "A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter", Mol Psychiatry, 25, pp.2101~2118 (2020)
77. Uchida H, "Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia", J Clin Psychiatry, 69, pp.1281~1286 (2008)
78. Servonnet A, "Continuous versus extended antipsychotic dosing in schizophrenia : Less is more", Behav Brain Res, 401, pp.113076~ (2021)
79. Sasaki H, "Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol", Eur J Pharmacol, 282, pp.71~76 (1995)
80. Misawa F, "Tardive Dyskinesia and Long-Acting Injectable Antipsychotics : Analyses Based on a Spontaneous Reporting System Database in Japan", J Clin Psychiatry (2022)
81. Yang KC, "Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology(TSBPN)", CNS Drugs, 35, pp.893~905 (2021)
82. Correll CU, "Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics", CNS Spectr, 24, pp.354~370 (2019)
83. Hiemke C, "Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology : Update 2017", Pharmacopsychiatry, 51, pp.e1~ (2018)
84. de Leon J, "A Critical Commentary on the 2017 AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology", Pharmacopsychiatry, 51, pp.63~68 (2018)
85. Baldelli S, "Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?", Pharmacopsychiatry, 51, pp.270~271 (2018)
86. Schoretsanitis G, "A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone", Expert Rev Clin Pharmacol, 10, pp.965~981 (2017)
87. Baldelli S, "Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings : A 5-year single centre experience", World J Biol Psychiatry, 22, pp.34~45 (2021)
88. Mauri MC, ""Long-acting"olanzapine in maintenance therapy of schizophrenia : A study with plasma levels", Int J Psychiatry Clin Pract, 19, pp.99~105 (2015)
89. Hyza M, "Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care : A Retrospective Analysis", Neuropsychiatr Dis Treat, 17, pp.1069~1075 (2021)
90. D’Anna G, "Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotics as a Predictor of Relapse in Schizophrenia Spectrum Disorders : A 1-Year Pilot Study", Ther Drug Monit, 44, pp.805~810 (2022)
91. Waggershauser M, "Breakthrough psychosis under antipsychotic maintenance treatment and social stress", Psychol Med, 49, pp.2808~2809 (2019)
92. Correll CU, "Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia : Systematic Overview and Quality Appraisal of the Meta-analytic Evidence", JAMA Psychiatry, 74, pp.675~684 (2017)
93. Galling B, "Antipsychotic augmentation vs. monotherapy in schizophrenia:systematic review, meta-analysis and meta-regression analysis", World Psychiatry, 16, pp.77~89 (2017)
94. Correll CU, "Antipsychotic combinations vs monotherapy in schizophrenia : a meta-analysis of randomized controlled trials", Schizophr Bull, 35, pp.443~457 (2009)
95. Dong M, "Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients : Findings of the 2016 Research on Asian Psychotropic Prescription Patterns(REAP)survey", Asian J Psychiatr, 45, pp.74~80 (2019)
96. Grover S, "Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics : An Online Survey Study From India", J Clin Psychopharmacol, 39, pp.611~619 (2019)
97. Evernden C, "The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia", Ment Health Clin, 11, pp.305~310 (2021)
98. Schottle D, "Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, reallife non-interventional study", BMC Psychiatry, 18, pp.365~ (2018)
99. Haddad PM, "Nonadherence with antipsychotic medication in schizophrenia : challenges and management strategies", Patient Relat Outcome Meas, 5, pp.43~62 (2014)

관련 논문AI추천